We rationalized that by removing unfavorable (4R)-fluoro substituent at the (2S)-4,4-difluoropyrrolidine-2-carbonitrile moiety, the resulting (4S)-mono-fluorinated version of FAPI-04 may have higher FAP-inhibitory potency and exhibit better FAP-mediated tumor uptake. Here, FAP is linked to neoplasm.